Moderna, Inc.
Recent
price
P/E
ratio
div
yld
- -
ROIC.AI
Capital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- Similar Companies
- Business
- Moderna, Inc. (MRNA) develops and commercializes messenger RNA (mRNA) medicines and vaccines for infectious diseases, oncology, rare diseases, and other therapeutic areas; its core products include Spikevax (mRNA-1273), the COVID-19 vaccine approved for individuals 18 years and older; mRESVIA (mRNA-1345), the respiratory syncytial virus (RSV) vaccine for adults 60 years and older approved in the U.S., Europe, Canada, and Qatar; and mNEXSPIKE (mRNA-1283), the next-generation COVID-19 vaccine approved in the U.S.; the company advances a pipeline of over 45 development programs, including seasonal influenza and combination flu/COVID vaccines, cytomegalovirus vaccine candidates, individualized neoantigen therapies (INTs) such as intismeran autogene for oncology, and rare disease treatments targeting conditions like glycogen storage disease type 1a, with 36 ongoing clinical trials encompassing nine Phase 2 and Phase 3 oncology studies. Founded in 2010 and headquartered in Cambridge, Massachusetts, with manufacturing facilities in Norwood, Massachusetts, Moderna operates globally, partnering with governments and organizations in the U.S., UK, Canada, Australia, and Europe to support research, development, and commercial supply. Recent developments include closing a five-year $1.5 billion non-dilutive term loan facility with Ares Management Credit Funds in November 2025 to enhance liquidity to $7.1-7.6 billion; launching a three-year business strategy targeting up to 10% revenue growth in 2026 through geographic expansion and new product launches, aiming to grow its seasonal vaccine franchise from three to six approved products by 2028; investing $140 million to expand its Norwood facility for onshoring drug product capabilities, completing end-to-end domestic mRNA manufacturing; and discontinuing three pipeline assets—mRNA-1010 (seasonal influenza), mRNA-1083 (influenza/COVID combo), and mRNA-3745 (glycogen storage disease type 1a)—to prioritize high-impact programs amid cost management.
Company News
The real test for Moderna's cancer vaccine isn't about beating Keytruda. It's keeping cancer from coming back in the long term.
Moderna leaked data was positive, what's hurting MRNA stock then?
MRNA Tanks as Positive Phase III Cancer Therapy Data Fails to Impress
MRNA Plunges 20% in Two Days: Leak Shows Positive Cancer Vaccine Trial Results
Doctors call Moderna, Merck's cancer vaccine data a major advancement — even as stocks fall
Moderna's Cancer-Vaccine Leak Spurred Panic Selling as Wall Street Wanted a Cure
Moderna's Stock Just Stumbled. Is It a Buy on the Dip?
Moderna Sinks 4% After 18% Plunge as Melanoma Vaccine Selloff Extends; Merck and Pfizer Slip
Stock Futures Tumble as Crude Climbs Back Above $100
Did You Lose Money on Moderna, Inc. Stock? The Law Offices of Howard G.
Moderna Stock Cools After Cancer Vaccine Data Leak
Moderna Stock Slides Again Friday: What's Going On?
Tempus AI: Moderna's New Cancer Vaccine Partner Is The Pick Of The AI Biotech Bunch
Moderna Named a Top Employer by Science for Twelfth Consecutive Year
Moderna, Meta, SpaceX, AT&T, CoreWeave, Sandisk, and More Stocks That Explain Today's Market
Wall Street Breakfast Podcast: Moderna's Good News Goes Bad
Moderna stock just crashed 21% in a day; Here's why
Mizuho's Jared Holz: Moderna drop reflects high bar, not bad data
Moderna Stock Sinks Nearly 20% After Leak of Cancer-Vaccine Data
Stock Market Today, Oct. 22: Moderna Stock Plummets 18% on Melanoma Vaccine Data Leak Reports